针对乳腺癌的Treg向组合免疫疗法的综合性多奥米克分层和翻译评估
Nari Kim1, Seongwon Na2, Hyo Jin Lee3
1Biomedical Research Center, Asan Institute for Life Sciences, Asan Medical Center, Seoul, Republic of Korea.
Frontiers in oncology
|January 22, 2026
概括
这项研究确定了一种新的乳腺癌亚型,该亚型富含调节性T细胞 (Tregs),驱动免疫抑制. 将Treg向疗法与PD-1阻断相结合显示出治疗这种亚型的前景.
科学领域:
- 在瘤学瘤学.
- 免疫学 免疫学 免疫学
- 生物信息学是一种生物信息学.
背景情况:
- 由调节性T细胞 (Tregs) 驱动的免疫抑制性乳腺癌亚型尚不清楚,这阻碍了针对免疫调节疗法的患者的鉴定.
- Tregs在瘤微环境 (TME) 中调解免疫抑制,并与对免疫检查点抑制剂 (ICI) 的抵抗有关.
- 描述Treg介导的免疫抑制对于优化Treg向和组合免疫疗法至关重要.
研究的目的:
- 根据它们的免疫学概况,识别和描述不同的乳腺癌亚型.
- 评估Treg向疗法和PD-1阻断的疗效,单独或组合,用于免疫抑制性乳腺癌亚型.
主要方法:
- 无监督的多omics集成 (mRNA,miRNA,DNA甲基化,蛋白质组) 来识别乳腺癌亚型.
- 基于自动编码器的维度缩小和共识聚类来定义Treg丰富的子类型.
- 空间定量系统药理 (spQSP) 建模和使用EMT6同源模型与CCR8抑制剂 (IPG7236) 和抗PD-L1.1的实体研究.
主要成果:
- 一个Treg-丰富的亚型 (C2集群) 与高Treg透和免疫抑制信号被确定跨队列.
- 在基模拟预测了结合疗法 (Treg向+PD-1阻断) 的增强免疫激活和瘤控制.
- 在EMT6模型中,组合疗法 (IPG7236 + 抗PD-L1) 与单一疗法相比,显示出优异的瘤生长抑制.
结论:
- 一种Treg丰富的,免疫抑制性乳腺癌亚型通过多奥米克分析被确定.
- 在体和体内数据支持将Treg向疗法与PD-L1阻断相结合的治疗潜力.
- 以Treg为媒介的免疫抑制是治疗反应的关键因素,指导个性化组合策略.
相关概念视频
Targeted Cancer Therapies
8.7K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
8.7K
Tumor Immunotherapy
1.8K
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
1.8K
Translation
155.8K
Lesson: Translation
Translation is the process of synthesizing proteins from the genetic information carried by messenger RNA (mRNA). Following transcription, it constitutes the final step in the expression of genes. This process is carried out by ribosomes, complexes of protein and specialized RNA molecules. Ribosomes, transfer RNA (tRNA), and other proteins produce a chain of amino acids—the polypeptide—as the end product of translation.
Translation Produces the Building Blocks of...
Translation is the process of synthesizing proteins from the genetic information carried by messenger RNA (mRNA). Following transcription, it constitutes the final step in the expression of genes. This process is carried out by ribosomes, complexes of protein and specialized RNA molecules. Ribosomes, transfer RNA (tRNA), and other proteins produce a chain of amino acids—the polypeptide—as the end product of translation.
Translation Produces the Building Blocks of...
155.8K
Translation
17.6K
Translation is the process of synthesizing proteins from the genetic information carried by messenger RNA (mRNA). Following transcription, it constitutes the final step in the expression of genes. This process is carried out by ribosomes, complexes of protein and specialized RNA molecules. Ribosomes, transfer RNA (tRNA), and other proteins produce a chain of amino acids—the polypeptide—as the end product of translation.
Translation Produces the Building Blocks of Life
Proteins are...
Translation Produces the Building Blocks of Life
Proteins are...
17.6K
Initiation of Translation
38.4K
Initiating translation is complex because it involves multiple molecules. Initiator tRNA, ribosomal subunits, and eukaryotic initiation factors (eIFs) are all required to assemble on the initiation codon of mRNA. This process consists of several steps that are mediated by different eIFs.
First, the initiator tRNA must be selected from the pool of elongator tRNAs by eukaryotic initiation factor 2 (eIF2). The initiator tRNA (Met-tRNAi) has conserved sequence elements including modified bases at...
First, the initiator tRNA must be selected from the pool of elongator tRNAs by eukaryotic initiation factor 2 (eIF2). The initiator tRNA (Met-tRNAi) has conserved sequence elements including modified bases at...
38.4K
Termination of Translation
27.5K
The large ribosomal subunit has several important structures essential to translation. These include the peptidyl transferase center (PTC) - which is the site where the peptide bond is formed - and a large, internal, water-filled tube through which the nascent polypeptide moves. This latter structure is called the Peptide Exit Tunnel, and it begins at the PTC and spans the body of the large ribosomal subunit. During translation, as the nascent polypeptide chain is synthesized, it passes through...
27.5K


